NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement with InterWest Health to provide the preferred provider organization's members access to GTG's BrevaGen breast cancer diagnostic test.

The deal is the eighth that Melbourne, Australia-based GTG has reached with a US PPO. The deal was forged between its wholly owned subsidiary Phenogen Sciences and InterWest, a regional provider network based in Missoula, Mont. servicing seven states in the northwest US. InterWest's network includes more than 15,000 health care providers, GTG said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.